carboplatin + docetaxel + pyrotinib + trastuzumab

This is a four-drug combination regimen consisting of carboplatin, docetaxel, pyrotinib, and trastuzumab. It is used in the treatment of HER2-positive metastatic breast cancer. \n- **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis in rapidly dividing cells. \n- **Docetaxel** is a taxane-class chemotherapeutic that stabilizes microtubules and inhibits cell division. \n- **Pyrotinib** is an irreversible pan-ErbB tyrosine kinase inhibitor targeting HER1 (EGFR), HER2, and HER4 receptors, blocking downstream signaling pathways involved in tumor growth and survival[1][2][4]. \n- **Trastuzumab** is a monoclonal antibody targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting its signaling and mediating antibody-dependent cellular cytotoxicity[1][4]. \n\nThe combination leverages both targeted therapy against HER2 (pyrotinib plus trastuzumab) for comprehensive blockade of the HER2 pathway as well as cytotoxic chemotherapy (carboplatin plus docetaxel) to maximize antitumor efficacy. Clinical studies have shown this type of regimen can significantly improve progression-free survival compared to regimens lacking pyrotinib or using placebo instead[1][4].

Other names

TCbH plus pyrotinibpyrotinib-containing neoadjuvant therapy (with trastuzumab, docetaxel, and carboplatin)